Pharmaceutical Industry Information Portal


All posts by tag


Contract production of pharmaceutical ingredients by 2028 may reach $ 136 billion

The traditional active pharmaceutical ingredient dominated the market and accounted for the largest revenue share of 40.5% in 2020.

AGC Biologics Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities

AGC Biologics announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, currently owned by Novartis Gene Therapies.

Vectura to provide preclinical support for Incannex’s inhaled brain injury treatment

IHL-216A may make sports safer and reduce the morbidity and mortality rates of people suffering serious head traumas.

Yposkesi launches construction of its second commercial bioproduction site

Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, announces the launch of project SKY, the construction of...

Expert Articles